Actos Lawsuit

Background information on Actos lawsuits, settlements and litigation updates published between 2011 to 2016.

Actos Lawsuit Overview

The Actos litigation involved claims that the diabetes drug pioglitazone, manufactured by Takeda Pharmaceuticals and co-marketed by Eli Lilly, caused users to develop bladder cancer after long-term use.

Approved to help control blood sugar levels in adults with type 2 diabetes, Actos became one of the most widely prescribed medications in its class. However, emerging studies and internal company documents suggested that extended exposure to Actos significantly increased the risk of bladder tumors, leading patients and doctors to question whether the manufacturer had adequately disclosed these dangers.

As adverse event reports mounted, thousands of lawsuits were filed nationwide alleging that Takeda and Eli Lilly failed to warn patients and healthcare providers about the cancer risks associated with Actos. Plaintiffs claimed that the companies knew from early animal studies and human data that the drug posed serious carcinogenic potential but chose to conceal those findings to protect sales. The litigation expanded rapidly after the U.S. Food and Drug Administration announced in 2011 that long-term use of Actos for more than one year could be linked to bladder cancer.

The federal lawsuits were consolidated into multidistrict litigation (MDL No. 2299) in the Western District of Louisiana, where coordinated discovery and several bellwether trials were held. In 2015, Takeda agreed to a $2.4 billion global settlement to resolve approximately 9,000 claims, one of the largest pharmaceutical settlements at the time.

Actos Litigation Updates

September 15, 2015: Actos Bladder Cancer Settlement Approved by Federal Judge

A Louisiana federal judge granted final approval of a $2.4 billion settlement resolving thousands of Actos bladder cancer lawsuits filed nationwide against Takeda Pharmaceuticals. The agreement provided compensation for individuals who developed cancer after long-term Actos use, marking one of the largest product liability settlements in U.S. history involving a diabetes medication. The settlement followed years of litigation and multiple multimillion-dollar trial verdicts.

March 20, 2015: Additional Settlement Conferences Held in Actos MDL

The U.S. District Court for the Western District of Louisiana ordered additional settlement conferences to finalize a global resolution of remaining Actos bladder cancer claims. Negotiations followed extensive bellwether proceedings and growing pressure on Takeda to settle cases after facing damaging internal evidence disclosures. Attorneys indicated that most federal and state cases were expected to close under the settlement terms.

October 30, 2014: Federal Court Orders Actos Settlement Talks

Judge Rebecca Doherty directed parties in the Actos multidistrict litigation to engage in court-supervised settlement discussions. The order came after several early trials produced substantial jury awards for plaintiffs and revealed company emails indicating Takeda knew of potential cancer risks. The move signaled a turning point toward global resolution of the litigation.

March 27, 2014: Actos Litigation Conference Reviews Discovery and Bellwether Progress

The Actos MDL court convened a status conference to review ongoing discovery disputes, expert depositions, and coordination efforts with state court cases. Attorneys discussed progress on upcoming bellwether trials designed to test the strength of claims involving bladder cancer injuries. The conference highlighted the complexity and scope of evidence exchanged in the nationwide proceedings.

April 16, 2013: First Federal Actos Bladder Cancer Trial Scheduled

The court overseeing Actos bladder cancer lawsuits set the first federal bellwether trial, aimed at providing guidance for potential settlements in hundreds of similar claims. Plaintiffs alleged Takeda failed to warn doctors and patients about the cancer risks associated with long-term use of its diabetes drug. The outcome was expected to shape negotiations in both federal and state cases.

January 25, 2013: Federal Judge Allows Key Actos Evidence in MDL

A pretrial ruling permitted plaintiffs to present internal Takeda emails and marketing materials during trial that appeared to acknowledge a link between Actos and bladder cancer. The decision was considered a major victory for plaintiffs, giving juries access to internal corporate documents that might reveal what the company knew. Takeda denied wrongdoing, maintaining the drug’s benefits outweighed any risks.

July 13, 2012: Actos Bladder Cancer Litigation Advances in Federal Court

The number of Actos bladder cancer lawsuits continued to grow, with hundreds of new cases filed across the country. Plaintiffs claimed Takeda withheld critical safety data and continued to market Actos aggressively despite evidence of tumor formation in animal studies. Federal judges coordinated efforts to streamline pretrial discovery and deposition scheduling.

April 25, 2012: Second Actos Bladder Cancer Trial Scheduled in MDL

The federal court overseeing the Actos MDL announced a second bellwether trial to further evaluate liability and damages evidence. These early trials were designed to gauge jury reactions to expert testimony linking Actos to bladder cancer development. The results were expected to influence overall settlement discussions.

March 5, 2012: Internal Emails Reveal Takeda Knew of Actos Cancer Risks

Discovery documents revealed internal Takeda communications showing the company was aware of potential cancer concerns years before regulators were informed. Plaintiffs argued this evidence proved the drugmaker placed profits over patient safety. Takeda disputed those claims, asserting that Actos was properly tested and labeled.

February 9, 2012: Bellwether Trial Schedule Established for Actos Lawsuits

Judge Rebecca Doherty issued a case management order outlining the selection of representative lawsuits to serve as bellwether trials. The goal was to test legal theories, medical causation, and corporate conduct allegations common across hundreds of cases. Both sides prepared for an extensive discovery process to precede the trials.

January 4, 2012: Preservation of Actos Witness Testimony Approved

The court authorized videotaped depositions of key witnesses whose health or availability posed concerns for future trial proceedings. Attorneys viewed this as an important measure to preserve testimony from former Takeda employees and medical experts. The move ensured critical evidence would remain available during later phases of the MDL.

December 12, 2011: Discovery Phase Expands in Actos Bladder Cancer MDL

Discovery in the Actos litigation intensified as parties exchanged corporate records, clinical data, and internal communications. Plaintiffs’ attorneys focused on uncovering evidence of early warning signs in pre-market studies. The court also outlined procedures for expert witness disclosures and case deadlines.

November 7, 2011: California Court Schedules First Actos Bladder Cancer Trial

A California judge set a 2012 trial date for one of the first Actos bladder cancer lawsuits to reach a jury. The case was expected to influence the direction of the growing litigation nationwide. Attorneys prepared to present medical testimony linking long-term Actos use to tumor development.

June 15, 2011: More Than 1,000 Actos Bladder Cancer Lawsuits Filed

More than 1,000 lawsuits had been filed alleging that Takeda’s diabetes drug Actos caused bladder cancer after extended use. The litigation quickly became one of the largest pharmaceutical mass torts of the decade. Attorneys called for federal consolidation to streamline pretrial management.

December 30, 2011: Leadership Appointed in Actos MDL

Judge Rebecca Doherty appointed a team of plaintiffs’ lawyers to coordinate discovery, expert development, and settlement strategy. The leadership group was tasked with representing the interests of thousands of claimants consolidated in the MDL. The structure was intended to promote consistency across federal and state court actions.

December 30, 2011: Lawsuits Filed in California Over Actos Bladder Cancer Claims

New lawsuits were filed in California courts by patients who alleged that Actos caused them to develop bladder cancer after long-term use. Plaintiffs accused Takeda of downplaying risks to doctors and patients through misleading marketing practices. These state filings paralleled a growing number of federal claims nationwide.

December 30, 2011: Actos Litigation Centralized in Federal MDL

The Judicial Panel on Multidistrict Litigation ordered all federal Actos bladder cancer lawsuits consolidated in the Western District of Louisiana. Centralization aimed to reduce duplicative discovery and avoid inconsistent rulings in similar cases. Judge Rebecca Doherty was appointed to oversee coordinated proceedings.

December 30, 2011: Actos MDL Hearing Scheduled to Consider Consolidation

The Judicial Panel on Multidistrict Litigation scheduled arguments to determine whether federal Actos lawsuits should be combined into one centralized proceeding. Both plaintiffs and Takeda representatives presented positions on the advantages of consolidation. The motion reflected a surge of new claims being filed across multiple states.

December 30, 2011: Takeda Supports Consolidation of Actos Bladder Cancer Cases

Takeda agreed that consolidation was appropriate given the large number of lawsuits involving similar allegations. The company maintained, however, that Actos was safe and that no scientific evidence established a definitive causal link to bladder cancer. The move paved the way for nationwide coordination of claims.

December 30, 2011: Petition Filed to Centralize Actos Bladder Cancer Litigation

Plaintiffs’ attorneys petitioned the Judicial Panel on Multidistrict Litigation to form a multidistrict litigation for Actos lawsuits. The filing noted that cases shared nearly identical scientific questions and corporate conduct allegations. The request initiated what would become years of coordinated proceedings in federal and state courts.

Actos Verdicts and Settlements

August 3, 2016: Actos Trial Settlement Ends Ongoing Bladder Cancer Claims

A final settlement was reached in a long-running Actos bladder cancer case before it returned to trial. The agreement followed years of appeals and reduced damages, effectively ending one of the last unresolved claims against Takeda Pharmaceuticals. The resolution came as part of broader efforts to close out the remaining Actos lawsuits nationwide.

September 11, 2015: Actos Bladder Cancer Settlement Finalized in Federal Litigation

Takeda finalized a multibillion-dollar settlement that resolved thousands of lawsuits linking Actos to bladder cancer. The settlement provided financial compensation to plaintiffs who alleged the company concealed known cancer risks from regulators and the public. The agreement followed multiple verdicts that exposed internal company communications during trial.

February 27, 2015: Jury Awards Plaintiff in Actos Bladder Cancer Case Upheld

A Louisiana federal judge upheld a prior jury’s damage award in a landmark Actos case, rejecting Takeda’s attempts to overturn the verdict. The decision affirmed findings that the company acted with reckless disregard for patient safety. The ruling added pressure on Takeda to reach a global settlement for remaining cases.

October 29, 2014: $2 Million Actos Bladder Cancer Verdict Returned in Federal Court

A federal jury awarded $2 million to a Pennsylvania man who developed bladder cancer after taking Actos. Jurors found Takeda failed to warn consumers about the drug’s long-term cancer risks. The award reinforced earlier bellwether verdicts and demonstrated continued juror concern over the company’s handling of safety information.

June 10, 2014: Massive Actos Punitive Damage Award Ordered to Stand

A Louisiana federal judge refused to overturn a $9 billion punitive damages award issued against Takeda and Eli Lilly in an earlier Actos trial. Although the companies later appealed, the decision underscored the severity of findings that they concealed bladder cancer dangers. The verdict remained one of the largest product liability awards in U.S. history before being reduced on appeal.

April 15, 2014: Multiple Actos Defense Verdicts Returned in Bellwether Trials

Several juries found in favor of Takeda in early bellwether trials involving Actos bladder cancer allegations. Defense verdicts were issued in cases where jurors determined that plaintiffs failed to prove a direct causal link between Actos and their cancer diagnoses. These outcomes gave Takeda temporary momentum amid growing litigation losses elsewhere.

April 8, 2014: Jury Returns Landmark Punitive Damage Verdict in Actos Bladder Cancer Trial

A Louisiana jury awarded more than $9 billion in punitive damages to a man who claimed long-term Actos use caused his bladder cancer. Jurors concluded Takeda and Eli Lilly deliberately withheld cancer data from federal regulators to protect sales. The verdict sent shockwaves through the pharmaceutical industry and led to widespread media coverage.

November 19, 2013: Jury Clears Takeda in Actos Bladder Cancer Lawsuit

A California jury issued a defense verdict in one of the earliest Actos bladder cancer trials, finding insufficient evidence that the drug caused the plaintiff’s illness. The verdict followed weeks of expert testimony and scientific debate over causation. While Takeda prevailed in this case, the ruling did little to slow the momentum of other lawsuits nationwide.

April 26, 2013: Jury Awards Millions in First Actos Bladder Cancer Trial

A Los Angeles jury awarded $6.5 million to a former Actos user who developed bladder cancer, concluding that Takeda failed to adequately warn doctors about the risks. The verdict marked the first major victory for plaintiffs in the growing litigation. Evidence presented at trial showed that Takeda executives discussed delaying cancer risk disclosures to protect market share.

Actos Research and Reports

January 13, 2017: New Actos Cancer Warnings Issued After Long-Term Use Study

Researchers identified continued evidence linking long-term Actos use to an elevated risk of bladder cancer, prompting renewed safety discussions among regulators. The study emphasized the importance of limiting exposure duration and monitoring patients closely for urinary symptoms. The findings reinforced earlier concerns that persisted years after the drug’s initial FDA approval.

July 22, 2016: Actos Bladder Cancer Study Reaffirms Association With Diabetes Drug

A large-scale follow-up study published in BMJ again confirmed that patients taking Actos faced an increased likelihood of developing bladder cancer compared to those using other diabetes medications. Researchers noted that the risk rose with cumulative dose and duration of therapy. Takeda maintained that the benefits of Actos outweighed potential risks when used as directed.

October 24, 2013: Low Doses of Actos Still Linked to Bladder Cancer Side Effects

A new analysis revealed that even patients taking lower doses of Actos may face a measurable increase in bladder cancer risk. The findings challenged earlier assumptions that risk was confined to high-dose, long-term users. The study intensified scrutiny over whether any exposure to pioglitazone could be considered safe.

March 15, 2012: FDA Reports Spike in Actos Bladder Cancer Diagnoses

Federal health officials announced a rise in reports of bladder cancer among Actos users submitted to the FDA’s adverse event database. Investigators warned doctors to consider alternative treatments for diabetic patients with existing bladder conditions. The update added urgency to calls for additional regulatory action.

August 5, 2011: Actos Study Links Drug to Increased Bladder Cancer Diagnosis Rates

A new analysis of epidemiological data found higher-than-expected bladder cancer rates among Actos users, confirming earlier suspicions raised in premarket trials. The findings led to renewed warnings for patients and physicians about the drug’s potential risks. Experts urged closer patient monitoring and further study into dose-dependent effects.

February 23, 2011: Vision Problems Among Actos Users Prompt Side Effect Concerns

Researchers identified reports of blurred vision and diabetic macular edema among Actos users, adding to concerns about the drug’s safety profile. The findings highlighted broader issues with fluid retention and vascular side effects linked to the medication. The study increased awareness of potential complications beyond bladder cancer.

November 15, 2010: Actos Studies Continue to Highlight Elevated Bladder Cancer Risks

Two new studies strengthened the connection between long-term Actos use and bladder cancer, reinforcing ongoing FDA and European safety reviews. Both studies indicated a duration-dependent relationship, suggesting patients on the drug for more than two years faced the highest risk. Takeda faced growing international scrutiny as regulators evaluated next steps.

October 25, 2010: FDA Expands Actos Cancer Risk Warnings

The FDA required updated labeling for Actos to include stronger language about potential bladder cancer side effects. The decision followed multiple safety analyses and a steady rise in cancer reports. Physicians were urged to avoid prescribing the drug to patients with a history of bladder disease.

September 9, 2010: Actos Bladder Cancer Reports Increase as Sales Surge

New FDA data revealed hundreds of bladder cancer diagnoses linked to Actos use as the drug continued to generate billions in annual revenue. Patient advocates criticized Takeda for failing to adequately disclose the growing safety signal. The report fueled momentum for additional warnings and international restrictions.

July 6, 2010: Studies Identify Elevated Bladder Cancer Risk From Actos Exposure

Epidemiological studies in both the United States and Europe found a statistically significant increase in bladder cancer among Actos users. Researchers warned that prolonged exposure appeared to amplify the risk considerably. The findings became a central piece of evidence in subsequent product liability lawsuits.

June 28, 2010: Actos Profits Rise Amid Mounting Bladder Cancer Concerns

Despite growing scientific concern, Takeda reported record profits from Actos, which had become one of the most prescribed diabetes medications in the world. Analysts criticized the company for prioritizing financial performance while safety questions remained unresolved. The contrast between sales and emerging risk data drew widespread attention.

June 20, 2010: Health Officials Advise Against Actos Use Following Bladder Cancer Review

Health agencies in several countries urged doctors to suspend or avoid prescribing Actos after studies confirmed higher cancer risks with extended use. Regulators emphasized the importance of monitoring patients already on the medication. The advisory marked one of the earliest coordinated international responses to the growing controversy.

June 15, 2010: Actos Bladder Cancer Warning Approved by FDA

The FDA officially approved stronger bladder cancer warnings for Actos packaging, reflecting mounting evidence from clinical studies. The update represented a shift in regulatory tone, acknowledging risks previously downplayed in earlier communications. Physicians were cautioned to weigh benefits against long-term safety concerns.

June 10, 2010: European Regulators Issue New Actos Bladder Cancer Warnings

European Union officials expanded Actos safety warnings across member nations, requiring stricter oversight and patient education. The move came after France and Germany suspended sales amid mounting evidence of harm. The updated labeling brought European regulations in line with similar U.S. FDA actions.

June 2, 2010: France Recalls Actos Over Cancer Risk

French drug regulators ordered an immediate recall of Actos following findings of elevated bladder cancer risk among long-term users. The decision marked one of the first major withdrawals of the drug from an international market. Takeda responded by defending its research but faced intensifying global scrutiny.

June 1, 2010: Canada Reviews Actos Bladder Cancer Link

Health Canada launched an investigation into Actos following data suggesting a possible causal link between long-term use and bladder cancer. The review aimed to determine whether Canadian labeling required updates similar to those in Europe. Officials warned physicians to remain cautious until further findings were released.

May 31, 2010: FDA Adds Actos Bladder Cancer Warning After European Recall

The U.S. FDA followed France’s lead by requiring an immediate warning about bladder cancer risk for Actos users. The update came after multiple international regulators had already taken action. The warning instructed healthcare providers to avoid prescribing the drug to patients with current or past bladder cancer diagnoses.

May 20, 2010: Actos Sales Suspended in Europe Amid Cancer Concerns

Germany and France halted Actos sales after national studies linked the drug to increased bladder cancer rates. Both countries advised physicians to transition patients to alternative treatments. Takeda disputed the findings but acknowledged that further review was warranted.

December 1, 2009: FDA Reviews Actos Bladder Cancer Risk

The FDA announced it was reviewing data linking Actos to a potential increase in bladder cancer cases after early clinical signals emerged. Officials requested additional information from Takeda to determine whether label changes were necessary. The review marked the start of what would become a decade-long safety controversy surrounding the drug.

Actos Lawsuit Examples

February 5, 2019: Actos Bladder Cancer Lawsuit Filed Over Long-Term Use

A new lawsuit filed in 2019 alleged that years of Actos use caused the plaintiff to develop bladder cancer, reigniting attention to the drug’s risks long after the initial wave of litigation. The complaint claimed Takeda failed to warn consumers and doctors about the danger of extended use. The filing reflected continued legal action despite prior settlements in earlier cases.

February 6, 2012: Actos Wrongful Death Lawsuit Filed Over Fatal Bladder Cancer Diagnosis

The family of a former Actos user filed a wrongful death lawsuit after their loved one died from bladder cancer allegedly caused by the diabetes drug. The suit accused Takeda Pharmaceuticals of concealing known risks and failing to alert the medical community to emerging safety data. The case sought damages for negligence, failure to warn, and wrongful death.

September 9, 2011: Lawsuit Filed Alleging Bladder Cancer From Actos Side Effects

A product liability lawsuit was filed by a woman who developed bladder cancer following prolonged use of Actos for type 2 diabetes. The complaint alleged that Takeda knew about the potential cancer risks for years but failed to update its warnings until forced by regulators. The filing added to a growing number of similar cases nationwide.

December 30, 2010: Actos Bladder Cancer Class Action Lawsuit Filed in Federal Court

A class action lawsuit was filed seeking damages for individuals who developed bladder cancer after taking Actos, accusing Takeda of withholding safety data from regulators and consumers. The plaintiffs requested compensation for medical expenses and punitive damages for corporate misconduct. The case marked one of the earliest attempts to consolidate claims on behalf of all affected users.

December 23, 2010: Actos Class Action Lawsuit Filed Over Bladder Cancer Risks

Another class action was filed in the wake of mounting global recalls, alleging Takeda intentionally downplayed the bladder cancer risks associated with Actos. Plaintiffs claimed the company misled healthcare providers about the severity of potential side effects. The filing sought restitution and increased transparency from the drugmaker.

December 15, 2010: Individual Actos Lawsuit Filed Over Bladder Cancer Diagnosis

A California man filed one of the first individual lawsuits claiming Actos caused his bladder cancer after long-term use of the drug. The complaint alleged Takeda ignored evidence from clinical trials and failed to issue timely warnings. It was among the earliest cases to highlight internal corporate communications suggesting risk awareness.

December 13, 2010: Actos Lawsuit Filed Over Bladder Cancer Complications

A product liability lawsuit was filed against Takeda Pharmaceuticals by a patient who developed bladder cancer after taking Actos for several years. The case accused the company of negligence and fraud in concealing data that linked the drug to cancer development. It helped lay the groundwork for what became a massive nationwide litigation effort.